Patients with active relapsing multiple sclerosis who were taking interferon beta were randomly assigned to receive add-on subcutaneous daclizumab 2 mg/kg every 2 weeks ( interferon beta and high-dose daclizumab group ) , daclizumab 1 mg/kg every 4 weeks ( interferon beta and low-dose daclizumab group ) , or interferon beta and placebo for 24 weeks .
